Copy the page URI to the clipboard
Guns, P-J.; Johnson, D.M.; Van Op den bosch, J.; Weltens, E. and Lissens, J.
(2012).
DOI: https://doi.org/10.1111/j.1476-5381.2011.01795.x
Abstract
BACKGROUND AND PURPOSE QT prolongation is commonly used as a surrogate marker for Torsade de Pointes (TdP) risk of non‐cardiovascular drugs. However, use of this indirect marker often leads to misinterpretation of the realistic TdP risk, as tested compounds may cause QT prolongation without evoking TdP in humans. A negative electro‐mechanical (E‐M) window has recently been proposed as an alternative risk marker for TdP in a canine LQT1 model. Here, we evaluated the E‐M window in anaesthetized guinea pigs as a screening marker for TdP in humans.
EXPERIMENTAL APPROACH The effects of various reference drugs and changes in body temperature on the E‐M window were assessed in instrumented guinea pigs. The E‐M window was defined as the delay between the duration of the electrical (QT interval) and mechanical (QLVPend) systole.
KEY RESULTS Drugs with known TdP liability (quinidine, haloperidol, domperidone, terfenadine, thioridazine and dofetilide), but not those with no TdP risk in humans (salbutamol and diltiazem) consistently decreased the E‐M window. Interestingly, drugs with known clinical QT prolongation, but with low risk for TdP (amiodarone, moxifloxacin and ciprofloxacin) did not decrease the E‐M window. Furthermore, the E‐M window was minimally affected by changes in heart rate or body temperature.
CONCLUSIONS AND IMPLICATIONS A decreased E‐M window was consistently observed with drugs already known to have high TdP risk, but not with drugs with low or no TdP risk. These results suggest that the E‐M window in anaesthetized guinea pigs is a risk marker for TdP in humans.
CORE (COnnecting REpositories)
CORE (COnnecting REpositories)
